{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-001706","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2022-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.251223+00:00","generated_at":"2026-06-27T00:59:11.583229+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Anika reports Q4 2021 revenue $35.8M (+10% YoY); full year $147.8M (+13%); guides FY2022 low-to-mid single digit growth","bullets":["Q4 2021 revenue $35.8M (+10% YoY); net loss $5.8M ($0.40 diluted) vs $15.7M loss prior year.","Full-year 2021 revenue $147.8M (+13% YoY); net income $4.1M ($0.28 diluted) vs $24.0M loss in 2020.","Adjusted net loss Q4 $3.2M ($0.23 diluted) vs adjusted net income $1.7M prior year; adjusted EBITDA loss $0.2M vs $4.0M.","FY2022 guidance: revenue growth low-to-mid single digit; Joint Preservation mid-single to low-double digit, OA Pain low-single digit.","Cash balance $94.4M; operating cash flow $9.0M for full year; completed enrollment of Cingal pilot trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-001706","json":"https://secwatch.observer/filing/0001171843-22-001706.json","markdown":"https://secwatch.observer/filing/0001171843-22-001706.md","text":"https://secwatch.observer/filing/0001171843-22-001706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184322001706/0001171843-22-001706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184322001706/f8k_030822.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:59:11.583229+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}